ClinicalTrials.gg
Not yet recruitingNCT07061639Updated Jul 11, 2025

A Study of QLS5133 Monotherapy in Advanced Solid Tumors

A Phase 1/2 interventional study of QLS5133 in Advanced Solid Tumors, sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-11.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
212
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The phase 1/2 clinical study includes three stages: Phase 1 dose escalation, phase 1 PK expansion and phase 2 cohort expansion:

  • Phase 1: Assesse safety, tolerability, PK, immunogenicity and preliminary efficacy of QLS5133 in advanced solid tumors. Phase 1 dose escalation will use ATD + BOIN, the maximum sample size for each dose group is 12. For Phase 1 PK expansion, 1 to 4 appropriate doses will be selected. After the DLT observation period in the selected dose group up to 12 subjects (including those subjects in the dose escalation stage) can be further enrolled for PK expansion.
  • Phase 2: Evaluates QLS5133's anti-tumor efficacy in subjects with advanced solid tumors. at least 2 dose groups will be expanded.
02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥ 18 years on the day of signing the ICF, male or female;
  • (ECOG) performance status (PS) score: 0 or 1;
  • , per v1.1;
  • Adequate organ function;
  • Recover from all reversible AEs from previous anti-tumor treatment (i.e., Grade ≤ 1, according to v5.0), excluding alopecia (any grade) and Grade ≤ 2 neuropathy peripheral, or who experience other abnormalities that are not or toxicities judged to have no risk by the investigator;
  • (LVEF) ≥ 50%;

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with drugs targeting CDH6 (including ADCs), or any drug containing topoisomerase I inhibitors (including ADCs);
  • Large and uncontrollable pleural, pericardial or abdominal effusion before the first dose (those who are stable for at least 2 weeks after drainage can be enrolled);
  • Progressive or symptomatic ;
  • bleeding symptoms or obvious bleeding tendency within 1 month before the first dose
  • History of significant cardiac disease, or poorly controlled diabetes mellitus;
  • History of recurrent diseases;
  • History of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML);
  • History of other active malignant tumors within 3 years before signing the form;
  • If female, is pregnant or breastfeeding;
  • Be allergic to any component of QLS5133 or its .
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
212 participants (estimated)

Study arms

  • Experimental
    Monotherapy Dose Finding

    Drug: QLS5133

  • Experimental
    PK expansion as Monotherapy

    Drug: QLS5133

  • Experimental
    Cohort expansion as Monotherapy

    Drug: QLS5133

Interventions

  • DrugQLS5133

    antibody drug conjugate (ADC)

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events and serious adverse events

    Incidence and severity of adverse events, serious adverse events, according to NCI-CTCAE Version 5.0

    Time frame: up to 2 years

  2. Maximum tolerated dose (MTD)

    Highest administered dose with \< 33% participants experiencing dose limiting toxicity (DLT) in the first 6 DLT evaluable participants

    Time frame: 28days

  3. Recommended Phase 2 Dose (RP2D)

    Based on the maximum tolerated dose, cumulative safety, and pharmacokinetic data

    Time frame: up to 2 years

  4. Objective Response Rate (ORR)

    Percentage of participants with best response of complete response (CR) or partial response (PR) according to RECIST 1.1

    Time frame: up to 2 years

Secondary outcomes

  1. Maximum Serum Concentration of QLS5133 (Cmax)

    PK assessment

    Time frame: 21 days

  2. Maximum Serum Concentration of QLS5133 at Steady State (Cmax,ss)

    PK assessment

    Time frame: 63 days

  3. Minimum Serum Concentration of QLS5133 at Steady State (Cmin,ss)

    PK assessment

    Time frame: 63 days

  4. Time of Maximum Serum Concentration of QLS5133 (Tmax)

    PK assessment

    Time frame: 21 days

  5. Terminal Half-life (T1/2) of Serum QLS5133

    PK assessment

    Time frame: 63 days

  6. Area under the Serum Concentration-Time curve from the time of dosing to the last measurable concentration (AUC0-t) for QLS5133

    PK assessment

    Time frame: 21 days

  7. Area under the Serum Concentration-Time curve from the time of dosing extrapolated to time infinity (AUC0-∞) for QLS5133

    PK assessment

    Time frame: 63 days

  8. Apparent Volume of Distribution (Vd) of QLS5133

    PK assessment

    Time frame: 63 days

  9. Clearance (CL) of QLS5133

    PK assessment

    Time frame: 63 days

  10. Duration of Response (DOR)

    Time from CR or PR to objective disease progression or death to any cause

    Time frame: up to 2 years

  11. Progression Free Survival (PFS)

    PFS is defined as the time from the start of the treatment until objective disease progression or death from any cause

    Time frame: up to 2 years

  12. Time to Progression (TTP)

    Time from start of treatment to disease progression

    Time frame: 1 years

  13. 1 Year Overall Survival (1YOS)

    Proportion of participants alive at 1 year from the start of treatment to death from any cause

    Time frame: 1 years

  14. 2 Year Overall Survival (2YOS)

    Proportion of participants alive at 2 years from the start of treatment to death from any cause

    Time frame: 2 years

  15. Number of anti-drug antibody (ADA) Positive Participants

    Immunogenicity will be measured by the number of participants that are ADA positive

    Time frame: up to 2 years

  16. Number of neutralizing antibody (Nab) Positive Participants

    Immunogenicity will be measured by the number of participants that are Nab positive

    Time frame: up to 2 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2025; primary completion for Jul 2027, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2025
First posted
Jul 11, 2025
StartEst.
Jul 2025
Primary completionEst.
Jul 2027
CompletionEst.
Apr 2028
Last update
Jul 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07061639
Responsible party
Sponsor
First posted
Jul 11, 2025
Start date
Jul 2025 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Jul 11, 2025

Study contacts

Xiaohua Wu, PhD
Contact
JJYIN555@163.com
021-64175590-88503

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion